Dawn Phenomenon, Reactive Hypoglycemia, and the Long-Term Risk Questions People Bring to Life Insurance Talks

There's a particular kind of discovery that tends to happen around week two of wearing a continuous glucose monitor for the first time. Everything about the daytime glucose pattern starts to feel reasonably familiar — the post-meal arcs, the mid-afternoon dip, the way coffee seems to nudge the line upward slightly. And then someone looks at their overnight graph and sees something they weren't expecting: a rise. Not after eating. Not during any obvious stress. Just a quiet, unmistakable climb in blood sugar beginning somewhere around four or five in the morning, well before the alarm goes off.

Or they notice something different — a crash two hours after lunch that lands noticeably below their pre-meal baseline. A shakiness, a slight clamminess, a strange hollow feeling in the chest that arrives right when the afternoon should be getting productive. They look at the CGM data. It confirms what the body was already broadcasting.

These two patterns — the dawn phenomenon and reactive hypoglycemia — are among the more surprising discoveries that health-aware adults encounter when they start looking closely at their glucose data. They're both well-established in the research literature. They're both part of normal human glucose physiology, though they vary considerably in degree across individuals. And they're both the kind of thing that, once discovered, tends to generate questions that go well beyond biology — including, increasingly, questions that find their way into conversations with life insurance advisors.

This piece is a clear-eyed, educational look at what these patterns are, how they work biologically, and what the landscape of questions around them looks like when they intersect with insurance considerations.

What Dawn Phenomenon Describes

The dawn phenomenon is one of those biological realities that exists quietly in virtually every human body but becomes visible only when you're actually watching glucose data in real time. In its most basic description, it refers to a natural rise in blood glucose that occurs in the early morning hours — typically between approximately 3 a.m. and 8 a.m. — driven by hormones the body releases as part of the process of waking up.

The mechanism goes like this. In the hours before dawn, the body begins preparing to transition from sleep to waking. Part of that preparation involves a surge of counterregulatory hormones — primarily cortisol, growth hormone, epinephrine, and norepinephrine — that collectively signal the liver to begin releasing stored glucose into the bloodstream. This is an evolutionary feature: the body is stocking the fuel line before the engine needs to run. The liver responds by ramping up gluconeogenesis and glycogenolysis — producing new glucose and breaking down glycogen stores — so that blood sugar is rising as the person wakes, priming the system for the demands of the day ahead.

In people with well-functioning insulin response, the pancreas compensates for this liver-driven glucose surge by releasing a corresponding amount of insulin. The glucose goes up, insulin rises proportionally, glucose is cleared into cells, and fasting blood sugar lands in a normal range before breakfast. The whole sequence happens invisibly, without any subjective experience of it. Clean, efficient, unremarkable.

In people with diabetes — particularly type 1 and type 2 — this compensatory insulin response is absent or impaired. The liver releases its morning glucose load, but the insulin needed to clear it doesn't arrive in sufficient quantity. The result is an elevated fasting glucose reading that the person experiences as high blood sugar first thing in the morning — even if they ate nothing after dinner the previous night.

Dawn Phenomenon in Non-Diabetic Adults

What often surprises people is learning that the dawn phenomenon isn't exclusive to people with diabetes. Research going back several decades has demonstrated that a version of this morning glucose rise occurs in non-diabetic individuals as well. A study examining non-diabetic volunteers found that after approximately 5:30 a.m., plasma glucose, insulin, and C-peptide concentrations all increased significantly, with corresponding rises in glucose production, glucose utilization, and insulin secretion. The underlying hormonal drivers — cortisol and catecholamines rising from their nocturnal lows between 4:00 and 6:30 a.m. — were identical to the mechanism described in diabetic populations.

The difference in non-diabetic individuals is the compensation: the pancreas responds promptly and adequately to the liver's morning glucose release, keeping the net fasting glucose within normal range. On a CGM graph, a non-diabetic person may still see a visible early-morning rise — a modest upward curve beginning in the 4 to 6 a.m. window — that flattens back toward baseline or slightly above it. It's the same biological story, with a healthier ending.

But here's where individual variation enters the picture and makes CGM data more complex to interpret. The degree of this morning rise varies considerably across individuals. Some people show a barely perceptible early-morning glucose uptick. Others — particularly those with insulin resistance, metabolic syndrome, prediabetes, or simply high physiological stress loads — show a more pronounced rise that may push fasting glucose meaningfully higher than it would otherwise appear. The dawn phenomenon isn't a binary — on in diabetics, off in everyone else. It's a continuum, and where any individual sits on that continuum reflects the interplay of their hormonal milieu, hepatic insulin sensitivity, and pancreatic reserve.

This is part of why fasting glucose, taken at one point in the morning, can look different on different days depending on when exactly the blood was drawn relative to the dawn hormone surge — a nuance that traditional point-in-time testing completely obscures, and that CGM makes strikingly visible.

Reactive Hypoglycemia in Simple Terms

Reactive hypoglycemia is a different animal — and the name is, in a way, both precise and slightly misleading. It's precise because the phenomenon is genuinely reactive: blood sugar drops in response to something that happened earlier, specifically the insulin surge that followed a carbohydrate-containing meal. It's slightly misleading because "hypoglycemia" implies a clinical severity — the kind of dramatic low blood sugar event associated with insulin overdose or fasting in diabetic patients — when what most non-diabetic people experience is a more subtle, functional dip rather than a medical emergency.

The basic sequence runs like this. A meal is consumed, particularly one rich in rapidly absorbed carbohydrates — refined starches, added sugars, foods that enter the bloodstream quickly and push glucose up sharply. The pancreas, sensing the incoming glucose spike, releases insulin. In reactive hypoglycemia, this insulin release is — for reasons that researchers are still untangling — somewhat excessive relative to the glucose load. The insulin overshoots. It clears glucose from the bloodstream with more aggressiveness than the situation warranted, driving blood sugar down past the pre-meal baseline and sometimes below it.

The body registers this drop. The brain, which monitors glucose levels with the kind of vigilance usually reserved for life-or-death situations, sends out distress signals in the form of counterregulatory hormone release — adrenaline, glucagon — to push glucose back up. The person experiences this correction sequence as the crash: the clamminess, the slight tremor in the hands, the hollow ache behind the sternum, the sudden desperate craving for something sweet or starchy. It arrives two to four hours after eating, typically, with a persistence that's hard to reason away.

The Insulin Timing Problem Behind Reactive Hypoglycemia

Understanding why the insulin response overshoots requires a brief look at the architecture of normal insulin secretion — because the problem in reactive hypoglycemia is less about total insulin quantity and more about its timing and regulation.

Healthy insulin secretion after a meal occurs in two phases. The first phase is rapid: a burst of pre-formed insulin released within the first few minutes of glucose entering the bloodstream, providing an immediate initial response to the incoming load. The second phase is slower and sustained: continued insulin production matching the ongoing rise in glucose over the following hour or so. The two-phase architecture allows for proportional, calibrated glucose clearance.

In early insulin resistance, the first-phase response is often the first to degrade — it becomes blunted and delayed. Without that rapid initial insulin burst, blood glucose rises higher in the early post-meal period. The pancreas, recognizing that glucose is still climbing when it should be leveling off, compensates by ramping up the second-phase release more aggressively. The result is a delayed but oversized insulin response that arrives late, drives glucose down hard, and produces the drop that defines reactive hypoglycemia.

Research has described reactive hypoglycemia occurring in three general forms: idiopathic — with no clear underlying cause and occurring around three hours after eating — alimentary, occurring within two hours, often in people who have had gastrointestinal surgeries that alter gastric emptying; and late reactive hypoglycemia, occurring three to five hours after a meal and associated with early insulin resistance. The late form is the one most commonly encountered in health-aware adults using CGM who notice the crash pattern without a prior diabetes diagnosis. And it's worth noting — at least it strikes me as worth noting — that this late pattern may represent an early functional signal of insulin dysregulation that predates any abnormal fasting glucose or A1C result.

Introducing the Temporal Glucose Signature Framework

Both the dawn phenomenon and reactive hypoglycemia share a structural feature that distinguishes them from the kinds of glucose metrics captured by standard blood tests: they're defined not by a single value but by a pattern unfolding across time. To understand why this matters for how people interpret their CGM data — and why life insurance conversations are beginning to grapple with it — it helps to think through what might be called the Temporal Glucose Signature Framework.

The framework proposes that glucose patterns exist at two levels of resolution. The first is the single-point level: a glucose value at a given moment — the fasting glucose drawn at 7 a.m., the A1C percentage on an annual lab report. These are metabolic snapshots, and they've been the primary currency of clinical glucose assessment for decades. The second is the temporal signature level: the characteristic shape of glucose behavior across time — how it rises, where it peaks, how quickly it returns to baseline, whether it overshoots on the way down, how it behaves overnight. This temporal signature can only be read from continuous data.

The dawn phenomenon is a temporal signature feature: a recognizable pattern of early-morning rise that a single fasting glucose value might capture poorly on a typical morning and miss entirely on a morning when the blood draw happened to occur before the hormone surge peaked. Reactive hypoglycemia is similarly a temporal signature feature: the defining event is the post-meal trough, which occurs hours after eating and is completely invisible to any test taken at a different time of day.

What makes the Temporal Glucose Signature Framework practically relevant is that it explains why CGM data contains information that standard lab panels cannot access — and why, when that data starts appearing in insurance applications and medical records, it raises genuinely new questions for underwriters and actuaries who have always worked with single-point values rather than continuous patterns.

Why People Discuss These Patterns With Life Insurers

The path from CGM data to a life insurance conversation is not as unusual as it might sound. Here's roughly how it tends to unfold, at least from what I've gathered over the years of watching this space develop.

Someone in their forties or fifties, curious about their metabolic health, uses a CGM for a few weeks. They notice a pronounced dawn phenomenon — fasting glucose consistently elevated in the morning despite clean dietary patterns and normal A1C. Or they notice a reactive hypoglycemia pattern after lunch, confirmed by the data, that makes their afternoons feel like wading through wet sand. They mention this to their doctor, who notes it in the medical record. Or they mention it during a life insurance application when asked about health history and monitoring.

Life insurance underwriting has traditionally relied on a relatively narrow set of glucose metrics: fasting glucose at the time of the medical exam, A1C if available, and urine glucose as a supplementary screen. The underwriting logic built around these markers reflects decades of actuarial data linking glucose dysregulation to long-term mortality risk — well-established associations that form the foundation of diabetic underwriting classifications.

CGM data introduces a different kind of information into this conversation. Metrics like time in range (TIR — the percentage of time glucose stays within a defined window), time in hypoglycemia, glycemic variability coefficients, and glucose management indicator (GMI) are all derivable from CGM data and provide a richer picture of glucose homeostasis than any single value. Reinsurance researchers have begun examining how these metrics might be incorporated into life insurance underwriting frameworks — acknowledging that the field is evolving and that long-term mortality data specifically tied to CGM-derived metrics in non-diabetic populations is still limited.

How Life Insurers Generally Approach Glucose Data

Life insurance underwriting uses glucose information differently than health insurance does. Where health insurance coverage eligibility is protected under ACA rules for most products, life insurance operates without those protections. Insurers can and do adjust premiums — or in extreme cases, decline applications — based on metabolic health indicators that suggest elevated long-term mortality risk.

For people with diagnosed diabetes, underwriting classifications and corresponding premium adjustments are relatively well-established and follow recognized actuarial frameworks. For people with prediabetes-range results, the picture is more nuanced: some insurers apply standard rates, some apply mildly elevated rates, and outcomes depend heavily on the overall metabolic profile — age, weight, blood pressure, lipid levels, and the context of the glucose finding.

For CGM-specific data — dawn phenomenon patterns, reactive hypoglycemia episodes, glucose variability metrics — the underwriting landscape is genuinely less settled. The reinsurance industry has acknowledged that underwriters need new frameworks for interpreting CGM-derived glucose information, and that the traditional single-value approach doesn't map well onto continuous monitoring data. What that means practically for any individual applicant depends on the specific insurer, their underwriting guidelines, and how the data is presented and contextualized.

What this landscape suggests — and this is more of an observation than a prescription — is that people who have CGM data showing notable glucose patterns may benefit from working with an independent insurance broker who is familiar with metabolic health underwriting, rather than navigating the application process without that context. The data isn't necessarily disqualifying. But it does need to be interpreted accurately.

Keeping the Focus on General Questions, Not Personal Risk

One of the consistent tensions in any educational discussion of dawn phenomenon, reactive hypoglycemia, and insurance is the pull toward interpreting these patterns as individual risk indicators. It's a natural impulse — someone notices a glucose pattern, learns about its biological implications, and immediately wants to know what it means for their future health.

The honest answer is that neither pattern, in isolation, constitutes a reliable individual risk predictor. Dawn phenomenon occurs to some degree in essentially all humans — it's a physiological feature of the sleep-wake transition, not a pathological event. Its clinical significance depends on its magnitude, its consistency, and whether it's occurring in a context of already-impaired insulin signaling. A modest early-morning glucose rise in a person with otherwise normal metabolic markers is a different biological signal than a pronounced rise in someone with established insulin resistance and elevated A1C.

Reactive hypoglycemia sits similarly on a continuum. The mild post-meal dip that many people experience after a large carbohydrate-heavy meal — the two-o'clock heaviness, the foggy restlessness — is a common and generally benign aspect of glucose variability. The more pronounced pattern that occurs in the context of impaired first-phase insulin secretion may reflect early metabolic dysfunction worth monitoring. But neither pattern, observed on a CGM over two weeks, tells a complete story about long-term metabolic risk without the broader clinical context that only a physician can provide.

The Temporal Glucose Signature Framework — the idea that glucose patterns carry information that single-point values miss — is valuable precisely because it expands what can be known about metabolic function. But expanded data requires expanded interpretive sophistication, both on the part of the individual reading their own CGM graph and on the part of any system — clinical or actuarial — trying to derive meaning from it.

Frequently Asked Questions

What is the dawn phenomenon and does it only affect people with diabetes?

The dawn phenomenon refers to a natural rise in blood glucose occurring in the early morning hours — typically between 3 and 8 a.m. — driven by a surge of hormones including cortisol, growth hormone, and catecholamines that signal the liver to release glucose in preparation for waking. Research has demonstrated that a version of this phenomenon occurs in virtually all humans, including non-diabetic individuals. In people without diabetes, compensatory insulin secretion keeps the morning rise within normal range. In people with diabetes, impaired insulin response results in a more pronounced and clinically significant elevation.

What causes reactive hypoglycemia and who experiences it?

Reactive hypoglycemia describes a drop in blood glucose occurring two to five hours after a meal, caused by an insulin response that overshoots the glucose load delivered by the meal. The underlying mechanism often involves a disruption of the normal two-phase insulin secretion pattern — particularly a blunted or delayed first-phase response — that leads to an excessive delayed insulin surge. It can occur in people without a diabetes diagnosis, particularly those with early insulin resistance, and is often experienced as shakiness, clamminess, intense hunger, or difficulty concentrating in the hours following a meal.

If my CGM shows a dawn phenomenon or reactive hypoglycemia pattern, does it mean I have a metabolic problem?

Not necessarily, and this distinction matters. Both patterns exist on a continuum of normal human glucose physiology. A modest dawn rise or a mild post-meal dip may simply reflect individual variation in glucose dynamics without indicating metabolic dysfunction. The clinical significance of either pattern depends on its magnitude, consistency, and the broader metabolic context — including fasting glucose, A1C, insulin sensitivity indicators, and overall risk factor profile. CGM data that raises questions is best interpreted with a clinician who can provide that broader context, rather than as a standalone self-diagnosis tool.

How does CGM data factor into life insurance applications?

Life insurance underwriting has historically used single-point glucose metrics — fasting glucose and A1C — as primary inputs for assessing metabolic risk. CGM-derived metrics, including time in range, glucose variability, and specific patterns like dawn phenomenon or hypoglycemic episodes, represent a newer category of data that the insurance industry is actively developing frameworks to interpret. For people with CGM data, outcomes in life insurance underwriting depend on the specific insurer's guidelines, the overall metabolic profile, and how the data is contextualized. Working with an independent broker familiar with metabolic underwriting is generally advisable when CGM data is part of the health history.

What is time in range and why is it relevant to insurers?

Time in range (TIR) is a CGM-derived metric representing the percentage of time blood glucose stays within a defined target range — typically 70 to 180 mg/dL for people with diabetes. Reinsurance researchers have identified TIR as a potentially valuable supplementary metric in life insurance underwriting, with higher TIR associated with better glycemic stability and, in some research, lower complication risk in diabetic populations. For non-diabetic populations, the actuarial significance of TIR is less established, and the insurance industry is still developing consensus on how to incorporate it into risk assessment frameworks alongside traditional glucose markers.

Can stress affect the dawn phenomenon or reactive hypoglycemia patterns?

Research suggests yes, to a meaningful degree. The hormones that drive the dawn phenomenon — cortisol and catecholamines — are also the primary stress-response hormones. Periods of elevated psychological or physiological stress can amplify the morning cortisol surge, producing more pronounced dawn glucose rises that a CGM will capture clearly. For reactive hypoglycemia, stress can indirectly worsen patterns by disrupting sleep quality (which affects insulin sensitivity the following day) and by producing rapid eating behaviors that increase the likelihood of large carbohydrate loads producing oversized insulin responses.

What the Data Is Trying to Say

The dawn phenomenon and reactive hypoglycemia are, at their core, communications from the body's glucose regulation system — messages written in the language of blood sugar curves rather than words. The dawn rise says: here is how my liver and hormonal system prepare me for waking, and how well my pancreas compensates for that preparation. The post-meal dip says: here is how my insulin secretion pattern responds to a glucose challenge, and whether the timing and magnitude of that response is well-calibrated.

Neither message is simple. Both require context to interpret — the broader metabolic picture, the consistency and degree of the pattern, the presence or absence of other risk indicators. And both are becoming visible to more people because of the growing use of CGM technology, which is surfacing information that always existed but was previously invisible to anyone without continuous monitoring.

The questions these discoveries generate — biological, clinical, insurance-related — are legitimate and worth asking. The answers, more often than not, live at the intersection of a careful clinician's judgment and a person's genuine engagement with their own metabolic patterns over time. No single data point, however elegantly captured, tells the whole story on its own.